Per WSJ:
News late Thursday that Pfizer is planning to price its shot at $110 to $130 per dose in the U.S. is giving a lift to both stocks as investors rework their models to reflect the higher revenue starting next year when Pfizer expects to transition its vaccine to the commercial market. The federal government currently covers the cost of vaccines and is paying roughly $30 per dose under the latest contract.
While investors had expected a hike as that coverage lapsed, “the magnitude of the price increase was well above expectations,” wrote Chris Schott, an analyst at JPMorgan. Pfizer was up 4.5% while Moderna rose 9% in early afternoon trading.
See PFE flow: unusualwhales.com/flow
PFE raises covid vaccine four times the current selling price and 100 times the estimated cost of manufacturing the vaccine
10/24/2022
